Advertisement

Topics

Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy

01:00 EDT 1 Jun 2015 | Hoffmann-La Roche Ltd

Roche today announced new results from the Phase II NeoSphere study. The results suggest that Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel chemotherapy given prior to surgery reduced the risk of disease getting worse and increased the time people lived without their cancer returning compared to Herceptin and chemotherapy in people with HER2-positive early breast cancer (eBC).

Original Article: Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy

NEXT ARTICLE

More From BioPortfolio on "Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy"

Advertisement
Quick Search
Advertisement
Advertisement